Genetically modified human T lymphocytes engineered to express a chimeric antigen receptor that recognizes two undisclosed tumor-associated antigens. Upon binding antigen on colorectal or pancreatic tumor cells, the CAR activates T-cell effector functions (cytokine release, proliferation, and perforin/granzyme-mediated lysis), producing selective immune-mediated antitumor cytotoxicity and aiming to reduce antigen-escape through dual targeting.